GE Healthcare and M+W Group Form Strategic Alliance in Vaccines, Insulin and Biopharmaceuticals

GE Healthcare, the healthcare business of GE and M+W Group, a leading global engineering, construction and project management company, announced today that the companies have formed a strategic alliance aimed at overcoming the lack of key biopharmaceuticals, especially in emerging nations.

The alliance, which will combine GE Healthcare’s expertise in technologies for biopharmaceutical manufacture with M+W Group’s global capabilities in bio-engineering and construction, will assist countries worldwide to become self-sufficient in the manufacture of vital biopharmaceuticals such as vaccines, insulin and biosimilars.

This press kit contains materials and information related to this announcement.

PRESS CONTACT: Val Jones (val.jones@ge.com): +44 791 717 5192

GE Healthcare, the healthcare business of GE and M+W Group, a leading global engineering, construction and project management company, announced today that the companies have formed a strategic alliance aimed at overcoming the lack of key biopharmaceuticals, especially in emerging nations.

The alliance, which will combine GE Healthcare’s expertise in technologies for biopharmaceutical manufacture with M+W Group’s global capabilities in bio-engineering and construction, will assist countries worldwide to become self-sufficient in the manufacture of vital biopharmaceuticals such as vaccines, insulin and biosimilars.

This press kit contains materials and information related to this announcement.

PRESS CONTACT: Val Jones (val.jones@ge.com): +44 791 717 5192